Trials / Terminated
TerminatedNCT02284425
Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 25 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of REGN1193 in patients with Type 2 Diabetes Mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1193 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2014-11-06
- Last updated
- 2016-05-12
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02284425. Inclusion in this directory is not an endorsement.